Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis

Peer Review reports

Original Submission
31 Aug 2024	Submitted	Original manuscript
24 Sep 2024	Reviewed	Reviewer Report - Anthony F. Markus
7 Oct 2024	Reviewed	Reviewer Report
13 Oct 2024	Reviewed	Reviewer Report
25 Oct 2024	Author responded	Author comments - Hazem E. Mohammed
25 Oct 2024	Author responded	Author comments - Hazem E. Mohammed
Resubmission - Version 2
25 Oct 2024	Submitted	Manuscript version 2
31 Oct 2024	Reviewed	Reviewer Report - Anthony F. Markus
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
24 Feb 2025	Editorially accepted
26 Mar 2025	Article published	10.1186/s13005-025-00494-w

Back to article page